NCT05789914

Brief Summary

The most commonly used barrier membrane material in guided tissue regeneration is absorbable collagen membrane. Although the collagen membrane has a good barrier effect, it lacks the growth factors needed for periodontal tissue regeneration, which affects the effect of collagen membrane on periodontal tissue regeneration. Extracellular Matrix Scaffold of Small Intestinal Submucosa (SIS) Membrane is a novel absorbable membrane that retains the extracellular matrix structure and is conducive to vascular ingrowth and tissue repair. The in vitro study showed that SIS membrane had excellent biocompatibility and certain antibacterial effect. Preclinical study also showed that SIS membrane significantly promoted the differentiation of bone marrow mesenchymal stem cells into osteoblasts, and promoted bone regeneration more effectively than collagen mechanism materials. SIS membrane can be used in soft tissue wound repair, guided bone regeneration, site preservation and other surgeries, and has achieved good therapeutic effects. However, whether the application of SIS membrane can achieve good therapeutic effect on periodontal guide tissue regeneration is still unclear. Therefore, in this study, the effects of guide tissue regeneration with collagen membrane and SIS membrane were compared through a randomized controlled clinical study.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 1, 2023

Completed
27 days until next milestone

Study Start

First participant enrolled

March 28, 2023

Completed
1 day until next milestone

First Posted

Study publicly available on registry

March 29, 2023

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2024

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2025

Completed
Last Updated

May 10, 2024

Status Verified

May 1, 2024

Enrollment Period

1.2 years

First QC Date

March 1, 2023

Last Update Submit

May 9, 2024

Conditions

Keywords

guided tissue regenerationSmall Intestinal SubmucosaRandomized Controlled Clinical Trial

Outcome Measures

Primary Outcomes (2)

  • clinical attachment loss

    before and 6 months after surgery, examine the changes of CAL

    Baseline and 6 months after surgery

  • clinical attachment loss

    before and 12 months after surgery, examine the changes of CAL

    baseline and 12 months after surgery.

Study Arms (2)

Small Intestinal Submucosa Membrane

EXPERIMENTAL
Procedure: Flap surgery+bone graft+guided tissue regeneration

Bio-guide

ACTIVE COMPARATOR
Procedure: Flap surgery+bone graft+guided tissue regeneration

Interventions

after flap elevation and debridement, intrabony defect was filled with Bio-Oss and covered with membrane.

Bio-guideSmall Intestinal Submucosa Membrane

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • periodontitis patients with stage III to IV, grade C had one or more intrabony defects with a depth of ≥3 mm; PD≥5mm after initial periodontal therapy.

You may not qualify if:

  • smokers, pregnant female, other systematic disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Peking University Hospital of stomatology

Beijing, Beijing Municipality, China

RECRUITING

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 1, 2023

First Posted

March 29, 2023

Study Start

March 28, 2023

Primary Completion

June 1, 2024

Study Completion

January 1, 2025

Last Updated

May 10, 2024

Record last verified: 2024-05

Locations